Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

5 Oct 2009 07:00

RNS Number : 1958A
Immunodiagnostic Systems Hldgs PLC
05 October 2009
 



 

Immunodiagnostic Systems Holdings plc

Trading update

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces a trading update for the six month period to 30 September 2009, prior to the release of its half-yearly report on Monday, 30 November 2009.

Turnover from continuing operations for the period is 56% ahead of the comparative period for last year at £16.9 million (2008: £10.8 million) and 20% ahead of 2008 H2 on a like for like basis. Revenues have increased in all direct sales territories with substantial growth in the USAFrance and Germany. Sales of our Vitamin D products continue to grow at an impressive rate, having doubled compared to same period last year.

The company has made progress in both sales and placements of our automated instrument the IDS-iSYS following its launch at the end of February this yearWe have also launched three automated products; 25 Hydroxy vitamin D at the end of February, P1NP in July and HGH in September. We have direct reagent rental accounts in the UK, FranceGermanyAustria 

and Switzerland and have made instrument sales in AustraliaCanadaFinlandItalySpainFrance and Switzerland.

The roll out of the IDS-iSYS is in its formative stages, and although initial machine sales are a little lower than anticipated, it is pleasing to report that revenue per machine is ahead of expectations. We expect the rate of sales and placements to increase in H2 following the increase in the number of iSYS evaluation sites towards the end of H1, the new agreement with Technogenetics (announced today on RNS Reach) under which we will supply OEM instruments and reagents to them, and, subject to the timing of FDA approval later this year, the planned US launch of the iSYS system.

Overall trading remains in line with management expectations and the Board remains confident going forward that it can continue to execute its plans for the current year.

Enquiries:

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

Roger Duggan, CEO

Paul Hailes, Finance Director

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTILFLTIRLSIIA
Date   Source Headline
10th Sep 20147:00 amRNSAcquisition of Dia.Metra S.r.l.
21st Aug 20147:00 amRNSChinese FDA clearance for the IDS-iSYS instrument
4th Aug 20145:59 pmRNSAGM Results
4th Aug 20147:00 amRNSAGM Statement
30th Jul 201410:25 amRNSAdditional Listing
14th Jul 201411:36 amRNS2014 Annual Report & Accounts and Notice of AGM
24th Jun 20147:00 amRNSFinal Results
12th May 201410:51 amRNSHolding(s) in Company
15th Apr 20147:00 amRNSTrading Statement
13th Mar 20144:40 pmRNSSecond Price Monitoring Extn
13th Mar 20144:35 pmRNSPrice Monitoring Extension
7th Mar 20147:00 amRNSDirectorate Change
15th Jan 20144:28 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSFDA clearance of Direct Renin assay on IDS-iSYS
8th Jan 201412:47 pmRNSAdditional Listing
19th Dec 20134:36 pmRNSAdditional Listing
12th Dec 20136:20 pmRNSHolding(s) in Company
12th Dec 20136:19 pmRNSHolding(s) in Company
27th Nov 20137:00 amRNSHalf Yearly Report
10th Oct 20137:00 amRNSTrading Statement
8th Oct 20134:29 pmRNSHolding(s) in Company
8th Oct 20134:26 pmRNSHolding(s) in Company
27th Sep 201312:40 pmRNSHolding(s) in Company
24th Sep 20131:15 pmRNSAdditional Listing
4th Sep 20137:00 amRNSHolding(s) in Company
28th Aug 201312:46 pmRNSAdditional Listing
31st Jul 201312:20 pmRNSAdditional Listing
29th Jul 20133:24 pmRNSHolding(s) in Company
26th Jul 20133:08 pmRNSResult of AGM
26th Jul 201312:00 pmRNSAGM Statement
2nd Jul 20139:41 amRNSDirector/PDMR Shareholding
28th Jun 20139:46 amRNSAdditional Listing
28th Jun 20139:00 amRNSAnnual Report and AGM
26th Jun 20137:00 amRNSAdditional Listing
24th Jun 20137:00 amRNSFDA clearance of 1,25-Dihydroxy Vitamin D assay
21st Jun 20137:00 amRNSImmunodiagnostic Systems streamlines Board
17th Jun 20137:00 amRNSFinal Results
10th May 20134:29 pmRNSHolding(s) in Company
9th May 20133:22 pmRNSAdditional Listing
2nd May 20137:41 amRNSEntry into Chinese Diagnostics Market
25th Apr 20134:17 pmRNSTrading Update - Replacement
23rd Apr 20139:45 amRNSHolding(s) in Company
16th Apr 20135:03 pmRNSHolding(s) in Company
16th Apr 201311:42 amRNSHolding(s) in Company
10th Apr 20137:00 amRNSDistribution Agreement
10th Apr 20137:00 amRNSTrading Statement
5th Apr 201310:22 amRNSDirector/PDMR Shareholding
4th Apr 20134:43 pmRNSHolding(s) in Company
11th Feb 20137:00 amRNSCollaboration with Diagnostica Stago
14th Dec 20122:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.